Arcus Biosciences, Inc. (RCUS)
24.41
+0.58
(+2.43%)
USD |
NYSE |
Oct 09, 16:00
24.42
+0.01
(+0.04%)
Pre-Market: 20:00
Arcus Biosciences EPS Diluted (Quarterly) : -0.7216 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.7216 |
| March 31, 2026 | -1.021 |
| December 31, 2025 | -0.8945 |
| September 30, 2025 | -1.268 |
| June 30, 2025 | 0.00 |
| March 31, 2025 | -1.138 |
| December 31, 2024 | -1.025 |
| September 30, 2024 | -1.007 |
| June 30, 2024 | -1.021 |
| March 31, 2024 | -0.0464 |
| December 31, 2023 | -1.08 |
| September 30, 2023 | -0.9517 |
| June 30, 2023 | -1.025 |
| March 31, 2023 | -1.096 |
| December 31, 2022 | -0.9292 |
| September 30, 2022 | -0.8987 |
| June 30, 2022 | -0.9278 |
| March 31, 2022 | -0.955 |
| Date | Value |
|---|---|
| December 31, 2021 | 3.707 |
| September 30, 2021 | -1.112 |
| June 30, 2021 | -1.089 |
| March 31, 2021 | -1.082 |
| December 31, 2020 | -0.8162 |
| September 30, 2020 | 0.028 |
| June 30, 2020 | -0.9283 |
| March 31, 2020 | -0.6267 |
| December 31, 2019 | -0.3767 |
| September 30, 2019 | -0.5087 |
| June 30, 2019 | -0.6414 |
| March 31, 2019 | -0.4061 |
| December 31, 2018 | -0.2848 |
| September 30, 2018 | -0.2524 |
| June 30, 2018 | -0.32 |
| March 31, 2018 | -1.365 |
| December 31, 2017 | -0.3019 |
| September 30, 2017 | -11.86 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Halozyme Therapeutics, Inc. | 1.897 |
| AVITA Medical, Inc. | -0.2492 |
| Iovance Biotherapeutics, Inc. | -0.1051 |
| Editas Medicine, Inc. | -0.1528 |
| Recursion Pharmaceuticals, Inc. | -0.246 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -91.00M |
| Revenue (Quarterly) | 41.00M |
| Total Expenses (Quarterly) | 132.00M |
| Enterprise Value | 2.512B |
| Gross Profit Margin (Quarterly) | 95.12% |
| Profit Margin (Quarterly) | -222.0% |
| Earnings Yield | -16.00% |
| Normalized Earnings Yield | -16.00 |